205 related articles for article (PubMed ID: 15694833)
1. The serine/threonine kinase Pim-1.
Bachmann M; Möröy T
Int J Biochem Cell Biol; 2005 Apr; 37(4):726-30. PubMed ID: 15694833
[TBL] [Abstract][Full Text] [Related]
2. Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis.
Popivanova BK; Li YY; Zheng H; Omura K; Fujii C; Tsuneyama K; Mukaida N
Cancer Sci; 2007 Mar; 98(3):321-8. PubMed ID: 17270021
[TBL] [Abstract][Full Text] [Related]
3. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
[TBL] [Abstract][Full Text] [Related]
4. The PIM family of serine/threonine kinases in cancer.
Narlik-Grassow M; Blanco-Aparicio C; Carnero A
Med Res Rev; 2014 Jan; 34(1):136-59. PubMed ID: 23576269
[TBL] [Abstract][Full Text] [Related]
5. Understanding the functional discrepancy of Pim-1 in cancer.
Ouhtit A; Muzumdar S; Gupta I; Shanmuganathan S; Tamimi Y
Front Biosci (Elite Ed); 2015 Jan; 7(2):208-14. PubMed ID: 25553374
[TBL] [Abstract][Full Text] [Related]
6. The Pim kinases: new targets for drug development.
Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F
Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193
[TBL] [Abstract][Full Text] [Related]
7. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
Keeton EK; McEachern K; Dillman KS; Palakurthi S; Cao Y; Grondine MR; Kaur S; Wang S; Chen Y; Wu A; Shen M; Gibbons FD; Lamb ML; Zheng X; Stone RM; Deangelo DJ; Platanias LC; Dakin LA; Chen H; Lyne PD; Huszar D
Blood; 2014 Feb; 123(6):905-13. PubMed ID: 24363397
[TBL] [Abstract][Full Text] [Related]
8. For better or for worse: the role of Pim oncogenes in tumorigenesis.
Nawijn MC; Alendar A; Berns A
Nat Rev Cancer; 2011 Jan; 11(1):23-34. PubMed ID: 21150935
[TBL] [Abstract][Full Text] [Related]
9. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway.
Shay KP; Wang Z; Xing PX; McKenzie IF; Magnuson NS
Mol Cancer Res; 2005 Mar; 3(3):170-81. PubMed ID: 15798097
[TBL] [Abstract][Full Text] [Related]
10. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
[TBL] [Abstract][Full Text] [Related]
11. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
12. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.
Shah N; Pang B; Yeoh KG; Thorn S; Chen CS; Lilly MB; Salto-Tellez M
Eur J Cancer; 2008 Oct; 44(15):2144-51. PubMed ID: 18715779
[TBL] [Abstract][Full Text] [Related]
13. Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival.
Herzog S; Fink MA; Weitmann K; Friedel C; Hadlich S; Langner S; Kindermann K; Holm T; Böhm A; Eskilsson E; Miletic H; Hildner M; Fritsch M; Vogelgesang S; Havemann C; Ritter CA; Meyer zu Schwabedissen HE; Rauch B; Hoffmann W; Kroemer HK; Schroeder H; Bien-Möller S
Neuro Oncol; 2015 Feb; 17(2):223-42. PubMed ID: 25155357
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells.
Zhang G; Liu Z; Cui G; Wang X; Yang Z
Tumour Biol; 2014 Nov; 35(11):11137-45. PubMed ID: 25104088
[TBL] [Abstract][Full Text] [Related]
15. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
16. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
17. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.
Blanco-Aparicio C; Carnero A
Biochem Pharmacol; 2013 Mar; 85(5):629-643. PubMed ID: 23041228
[TBL] [Abstract][Full Text] [Related]
18. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
19. The PIM kinases in hematological cancers.
Alvarado Y; Giles FJ; Swords RT
Expert Rev Hematol; 2012 Feb; 5(1):81-96. PubMed ID: 22272708
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
